PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	13-23	thymoma viral proto-oncogene 1	Mus musculus	78-94	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	13-23	thymoma viral proto-oncogene 1	Mus musculus	96-99	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	13-23	thymoma viral proto-oncogene 1	Mus musculus	101-104	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	13-23	thymoma viral proto-oncogene 1	Mus musculus	140-143	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	13-23	thymoma viral proto-oncogene 1	Mus musculus	144-147	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	179-189	thymoma viral proto-oncogene 1	Mus musculus	78-94	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	179-189	thymoma viral proto-oncogene 1	Mus musculus	96-99	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	179-189	thymoma viral proto-oncogene 1	Mus musculus	101-104	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	179-189	thymoma viral proto-oncogene 1	Mus musculus	140-143	
19363269-5	2009	Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor LY294002 blocked the lovastatin-induced neuroprotective effect.	Lovastatin	179-189	thymoma viral proto-oncogene 1	Mus musculus	144-147	
29207042-0	2018	Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-kappaB and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264.7 macrophages.	Lovastatin	28-38	thymoma viral proto-oncogene 1	Mus musculus	120-123	
29207042-12	2018	Therefore, the present study demonstrates that lovastatin inhibits the expression of pro-inflammatory mediators, including iNOS and TNF-alpha, through the suppression of HDAC1 expression, PI3K/Akt phosphorylation and NF-kappaB translocation in LPS-stimulated RAW264.7 macrophage cells.	Lovastatin	47-57	thymoma viral proto-oncogene 1	Mus musculus	193-196	
22715163-8	2012	Lovastatin alone significantly reduced MPC and MTT cell viability at therapeutically relevant doses and inhibited both ERK and AKT signalling, but increased mTORC1/p70S6K signalling.	Lovastatin	0-10	thymoma viral proto-oncogene 1	Mus musculus	127-130	
22715163-9	2012	Combination treatment with NVP-BEZ235 and lovastatin showed a significant additive effect in MPC and MTT cells and resulted in inhibition of both AKT and mTORC1/p70S6K signalling without ERK up-regulation.	Lovastatin	42-52	thymoma viral proto-oncogene 1	Mus musculus	146-149